ReviewTranslational lung cancer research2026
Role and clinical significance of VISTA (PD-1H) and PVR (CD155) expression in non-small cell lung carcinoma: a systematic review.
Review in Translational lung cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immune checkpoint blockade has improved outcomes in non-small cell lung carcinoma (NSCLC), yet primary and acquired resistance remain common. VISTA (PD-1H) and CD155 (poliovirus receptor, PVR) are emerging immune-regulatory pathways that may contribute to immune escape and represent potential therapeutic targets. Thus, this systematic review aimed to evaluate the expression patterns, molecular functions, and clinical significance of CD155 (PVR) and VISTA (PD-1H) in NSCLC. Methods: We performed a systematic review of studies assessing the expression, function, and clinical relevance of VISTA and/or CD155 in NSCLC. PubMed, Scopus, Embase, and Web of Science were searched through September 2025. Original human, Results: Fifty-one studies met the inclusion criteria (22 VISTA; 29 CD155). VISTA was predominantly reported in stromal and immune-cell compartments and linked to immune-regulatory functions, but available evidence did not support a consistent association with survival. CD155 was mainly expressed on tumour cells, associated with an immunosuppressive microenvironment, and more consistently related to adverse prognosis in selected cohorts, particularly when co-expressed with programmed death-ligand 1 (PD-L1). Conclusions: Both pathways appear involved in immune modulation in NSCLC. Evidence for VISTA as a prognostic biomarker remains inconclusive, whereas CD155 shows a more reproducible association with unfavourable outcomes, supporting its further evaluation as a prognostic marker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.